Join Fund Library now and get free access to personalized features to help you manage your investments.

Add to My Watchlist

Alternative Equity Focus

NAVPS
(04-15-2024)
$4.82
Change
-$0.17 (-3.31%)

As at March 31, 2024

No data available


Fund Returns

Inception Return (December 18, 2020): -

Fund Returns
Row Heading Return Annualized Return
1 Mth 3 Mth 6 Mth YTD 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Yr 9 Yr 10 Yr
Fund - - - - - - - - - - - - - -
Benchmark 4.14% 6.62% 15.26% 6.62% 13.96% 3.95% 9.11% 16.99% 9.96% 9.65% 8.48% 9.70% 7.76% 7.67%
Category Average 2.33% 13.77% 13.77% 8.40% 14.38% 5.99% 5.81% 11.19% - - - - - -
Category Rank - - - - - - - - - - - - - -
Quartile Ranking - - - - - - - - - - - - - -

Monthly Return

Monthly Return
Return % Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar
Fund - - - - - - - - - - - -
Benchmark 2.90% -4.95% 3.36% 2.58% -1.37% -3.33% -3.21% 7.48% 3.91% 0.55% 1.82% 4.14%

Best Monthly Return Since Inception

-

Worst Monthly Return Since Inception

-

Calendar Return (%)

Calendar Return
Return % 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fund - - - - - - - - - -
Benchmark 10.55% -8.32% 21.08% 9.10% -8.89% 22.88% 5.60% 25.09% -5.84% 11.75%
Category Average - - - - - - 5.11% 17.27% -5.96% 6.54%
Quartile Ranking - - - - - - - - - -
Category Rank - - - - - - - - - -

Best Calendar Return (Last 10 years)

-

Worst Calendar Return (Last 10 years)

-

Asset Allocation

Sector Allocation

Geographic Allocation

Top Holdings

Equity Style

Equity style data not available

Fixed Income Style

Fixed income style data not available

Risk vs Return (3 Yr)

3 Yr Annualized

Standard Deviation - - -
Beta - - -
Alpha - - -
Rsquared - - -
Sharpe - - -
Sortino - - -
Treynor - - -
Tax Efficiency - - -
Volatility - - -

Risk Rating

Rating Not Available

Annualized Key Ratio Period Comparison

Key Ratio
Key Ratio 1 Yr 3 Yr 5 Yr 10 Yr
Standard Deviation - - - -
Beta - - - -
Alpha - - - -
Rsquared - - - -
Sharpe - - - -
Sortino - - - -
Treynor - - - -
Tax Efficiency - - - -

Fund Details

Start Date December 18, 2020
Instrument Type Mutual Fund (Alternative)
Share Class Commission Based Advice
Legal Status Trust
Sales Status Open
Currency CAD
Distribution Frequency Annual
Assets ($mil) -

Fund Codes

FundServ Code Load Code Sales Status
NEC216

Investment Objectives

The Fund seeks short and long-term capital appreciation through the ownership of biotechnology and life sciences companies. Investments by the Fund may be made globally. The Fund may use leverage through the use of cash borrowings, short sales and derivatives.

Investment Strategy

The portfolio manager uses the following investment strategies to achieve the Fund’s objective: Holdings will be comprised of a mix of biotechnology and life sciences companies; Sector exposure will include biotechnology, Speciality Pharma, Medical Devices, Medical Software and Technology, Diagnostics, Drug Delivery, Bioinformatics and Agricultural, Healthcare Services and Telehealth Services; Derivatives may be used for hedging purposes, to generate income and return enhancement.

Portfolio Manager(s)

Name Start Date
Next Edge Capital Corp. 10-18-2022

Management and Organization

Fund Manager Next Edge Capital Corp.
Advisor Next Edge Capital Corp.
Custodian -
Registrar -
Distributor -
Auditor -

Investment Minimums

RSP Eligible Yes
PAC Allowed No
PAC Initial Investment -
PAC Subsequent -
SWP Allowed No
SWP Min Balance -
SWP Min Withdrawal -

Fees

MER 2.03%
Management Fee 1.00%
Load Front Fee Only
FE Max 1.00%
DSC Max -
LL Max -
Trailer Fee Max (FE) 1.00%
Trailer Fee Max (DSC) -
Trailer Fee Max (NL) -
Trailer Fee Max (LL) -

Join Fund Library now and get free access to personalized features to help you manage your investments.